| A 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2025-021 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 2025年股东周年大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 20 日 | 境外上市外资股股东所持有表决权数量 | 662,195,156 | | --- | --- | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 40.7476 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 40.7476 | | （%） | | | 股股东所持有表决权数量占公司表决权数量的 其中：A | 3.1417 | | 比例（%） | | | 境外上市外资股股东所持有表决权数量占公司表 | 37.6059 | | 决权数量的比例（%） | | ...

董事会薪酬委员会 2025 年 6 月 20 日 诺诚健华医药有限公司（以下简称"公司"）董事会薪酬委员会依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相 关法律、法规、规范性文件的有关规定，对 2023 年科创板限制性股票激励计划 （以下简称"本激励计划"）首次授予部分第二个归属期及预留授予部分第一个 归属期符合归属条件的激励对象名单进行核查，经核查认为：本次拟归属的 138 名激励对象，符合《管理办法》《上市规则》等法律法规和规范性文件规定的激 励对象条件，符合本激励计划规定的激励对象范围，其作为公司本激励计划激励 对象的主体资格合法、有效。本激励计划首次授予部分第二个归属期及预留授予 部分第一个归属期的归属条件已成就。因此，公司董事会薪酬委员会同意本次归 属名单。 （以下无正文） 诺诚健华医药有限公司 诺诚健华医药有限公司董事会薪酬委员会 关于 202 ...

| | | 诺诚健华医药有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 诺诚健华医药有限公司（以下简称"诺诚健华"或"公司"）于 2025 年 6 月 20 日在公司会议室以现场会议结合通讯方式召开董事会。会议应出席董事 7 人，实 际出席董事 7 人，董事会主席 Jisong Cui（崔霁松）博士担任会议主席。会议的 召集、召开、表决程序符合有关法律、行政法规、部门规章、规范性文件和公司 章程的规定。 二、 董事会会议审议情况 (一) 审议通过《2023 年科创板限制性股票激励计划首次授予部分第二个 归属期及预留授予部分第一个归属期符合归属条件》的议案 根据《上市公司股权激励管理办法》《2023 年科创板限制性股票激励计划》 （以下简称"《激励计划》"）的相关规定和公司 2023 年股东周年大会的授权， 董事会认为公司 2023 年科创板限制性股票激励计划首次授予部分第二个归属期 及预留授予部分第一个归属期规定的归属条件已经成就，本次可归属数量分别为 1,682,250 ...

Core Insights - The Chinese biotechnology industry is expected to continue its recovery in the second half of 2025, driven by a resurgence in the Hong Kong IPO market and improved earnings outlook for biotech companies [3][15] - Key focus areas include the anticipated approval of new drugs, significant pipeline data releases, and increased merger and acquisition (M&A) activities, particularly related to the PD-1/VEGF pathways [3][15] Group 1: Market Trends - The Hong Kong IPO market is showing signs of recovery, with Hengrui's IPO raising HKD 9.8 billion, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [15] - Investor interest in the biotechnology sector remains high, as evidenced by the successful listing of antibody-drug conjugate pioneer, InnoCare, which saw its share price double on the first trading day [15] - M&A activities are expected to surge in 2025, particularly for companies involved in the PD-1/VEGF pathway, following positive data reported at the ASCO conference [5][15] Group 2: Company Performance and Projections - Chinese biotech companies are reaching a pivotal point of profitability, with Innovent Biologics expected to turn profitable in 2024, supported by the launch of its obesity drug and positive data from IBI 363 at ASCO [6] - BeiGene achieved breakeven in Q1 and is positioned to become a major player in global oncology, although its sales growth from 2025 to 2028 is projected to be below peers [6] - Companies like Akeso and Zai Lab are also expected to achieve profitability by 2025, despite facing valuation pressures due to tariff uncertainties [6] Group 3: Pipeline Developments - Innovent's obesity drug, Mazdutide, is anticipated to launch in China in early 2025, which could attract significant investor interest [9] - BeiGene's Sonrotoclax is expected to file for approval in China for treating relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma by mid-2026 [9] - Akeso is advancing multiple drugs through the pipeline, with filings for Cadonilimab and Ivonescimab expected in the second half of 2025 [10][13] Group 4: Valuation Metrics - The enterprise value/sales ratios for several Chinese biotech companies indicate varying growth expectations, with Sichuan Kelun-Biotech showing a high ratio of 35.5x and a projected sales CAGR of 54% from 2025 to 2028 [8] - The average enterprise value/sales ratio for Chinese peers stands at 13.0x, with a median of 11.8x, reflecting the competitive landscape within the industry [8]

The provided content does not contain any quantitative models or factors related to financial engineering or quantitative analysis. It primarily includes financial news, stock performance data, and general market updates. No relevant information about quantitative models, factor construction, or backtesting results is present in the documents.

Core Insights - Guolian Pharmaceutical Consumption Mixed A (015032) has experienced a decline of 1.35% on June 19, with a latest net value of 0.9 yuan, marking a cumulative drop of 7.36% over five consecutive trading days [1] - The fund was established in March 2022 with a total size of 0.28 billion yuan and has recorded a cumulative return of -9.51% since inception [1] - As of the end of 2024, institutional investors hold 0.04 billion shares, accounting for 12.38% of total shares, while individual investors hold 0.32 billion shares, making up 87.62% of total shares [1] Fund Manager Profile - The current fund manager, Mr. Pan Tianqi, holds a Bachelor of Science from Sichuan University, a Master of Science from the University of Pittsburgh, and an MBA from Katz Graduate School of Business [1] - Mr. Pan has previously worked as a researcher at Heng Rui Medicine Co., Ltd., and as a senior researcher and assistant fund manager at Guotai Junan Fund Management Co., Ltd. [1] - He joined He Xu Zhi Yuan Fund Management Co., Ltd. in July 2018 and has held various managerial positions, including the fund manager of the Zhongrong Pharmaceutical Consumption Mixed Securities Investment Fund since June 14, 2022 [1] Top Holdings - As of March 31, 2025, the top ten holdings of Guolian Pharmaceutical Consumption Mixed A account for a total of 48.85%, with significant positions in Heng Rui Medicine (7.78%), Zai Lab (6.18%), and BeiGene (4.69%) [2] - Other notable holdings include Haoyuan Pharmaceutical (4.50%), Aosaikang (4.45%), and Nocera Health (4.36%) [2] - The fund also holds shares in Guizhou Moutai (4.35%), Dize Pharmaceutical (4.31%), Yifang Bio (4.25%), and United Imaging Healthcare (3.98%) [2]

Group 1 - The core point of the news is that the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund has experienced a decline of 1.56% on June 19, with a cumulative drop of 9.38% over five consecutive trading days, and its latest net value is 1.64 yuan [1] - The fund was established in February 2022, with a total scale of 346 million yuan, and has recorded a cumulative return of -3.47% since inception [1] - As of the end of 2024, institutional investors hold 250 million shares of the fund, accounting for 97.27% of the total shares, while individual investors hold 7 million shares, accounting for 2.73% [1] Group 2 - The current fund manager, Ms. Zhang Wei, has a background in biomedical studies from Cornell University and has held various positions in the pharmaceutical research field before managing multiple funds since 2021 [2] - As of March 31, 2025, the top ten holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund account for a total of 64.17%, with significant investments in companies such as Heng Rui Pharmaceutical (10.23%) and Ke Long Pharmaceutical (9.09%) [2]

来源：金融界 公开信息显示，现任基金经理赵伟先生:中国,硕士研究生。历任葛兰素史克(上海)医药研发有限公司药 物化学部助理研究员、广发证券股份有限公司投资自营部医药研究员、招商基金管理有限公司研究部医 药组组长及招商基金管理有限公司国际业务部基金经理助理。现任农银汇理基金管理有限公司基金经 理。2019年11月8日至2021年3月5日担任农银汇理中小盘混合型证券投资基金基金经理。2020年1月13日 至2021年3月5日担任农银汇理行业成长混合型证券投资基金基金经理。2020年1月21日至2021年3月5日 任职农银汇理创新医疗混合型证券投资基金基金经理。2017年6月20日至2021年3月5日担任农银汇理医 疗保健主题股票型证券投资基金基金经理。曾任农银汇理中国优势灵活配置混合型证券投资基金基金经 理。2021年03月加入富国基金管理有限公司,2021年7月6日起担任富国精准医疗灵活配置混合型证券投 资基金基金经理。2024年04月23日起担任富国科创板两年定期开放混合型证券投资基金基金经理。 截止2025年3月31日，富国精准医疗混合C前十持仓占比合计69.71%，分别为：百利天恒（9.66%）、海 思科 ...

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 1.27% on June 19, with a latest net value of 2.56 yuan, marking a cumulative drop of 7.84% over five consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.724 billion yuan and a cumulative return of 156.40% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of March 31, 2025, the top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with major positions including: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuwell Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [3]

Core Viewpoint - The announcement details a change in the shareholding structure of Nuo Cheng Jian Hua Pharmaceutical Co., Ltd, indicating a reduction in the stake held by major shareholders, specifically King Limited and Success Growth Limited, from 8.08% to 7.54% [1][2]. Group 1: Shareholding Changes - The total shareholding percentage of King Limited and Success Growth Limited decreased from 8.08% to 7.54% [1][2]. - The number of shares held by these shareholders reduced from 14,239,205.4 thousand shares to 13,290.0430 thousand shares [1][2]. - The change in shareholding does not trigger mandatory tender offer obligations and does not violate any prior commitments [1]. Group 2: Impact on Company Governance - The primary shareholder has not changed, indicating that the governance structure and ongoing operations of the company will not be significantly affected [2]. - The company will continue to fulfill its information disclosure obligations regarding any future changes in shareholding [2].